Abstract Number: PB0783
Meeting: ISTH 2022 Congress
Background: Hepsin (HPN) is an extracellular serine-protease which dysregulation leads to tumor invasion and malignancy. Our group previously described HPN increases protumor and prothrombotic phenotypes in colorectal cancer (CRC) cells, and promotes invasion in zebrafish models. We also identified higher HPN plasma levels in metastatic vs. localized CRC patients, and in patients with thrombosis vs. no thrombosis.
Aims: To identify new HPN inhibitors that reduced its protumor and prothrombotic effects in CRC cells.
Methods: We performed a virtual screening to identify potential compounds that blocked HPN active site. The most outstanding compounds were tested in a fluorogenic assay that measured HPN proteolytic activity. Then, we measured HPN inhibitors effect on CRC cell line Caco-2 transfected with HPN-expression vector (Caco-2-HPN; HPN-overexpression) and negative-control vector (Caco-2; HPN-endogenous expression). We conducted wound confluence, gelatin matrix, cell cytometry and thrombin generation assays (TGA) for measuring migration, invasion, proliferation and procoagulant cell phenotypes, respectively. Finally, zebrafish models were used to test whether HPN inhibitors interfered with distant tumor dissemination.
Results: Virtual screening highlighted suramin as the most effective HPN inhibitor, with a docking score= -12 Kcal/mol. Fluorogenic assay confirmed suramin inhibited HPN in an irreversible and dose-dependent way (IC50=0.66 µM; 95%IC=0.42-1.32). In Caco-2 and Caco-2-HPN cells, suramin reduced migration and, significantly, invasion phenotypes (Figure 1A,B). These effects were more pronounced in Caco-2-HPN cells. Also in both cell types, suramin increased lag time and reduced endogenous thrombin potential and thrombin peak in TGA. Moreover, suramin increased time to peak and reduced velocity to peak in Caco-2-HPN cells (Figure 2A). Finally, suramin reduced Caco-2-HPN invasion to Caco-2 levels in zebrafish (Figure 2B).
Conclusion(s): Suramin is a HPN inhibitor that reduces invasive, migratory and procoagulant characteristics of CRC cells in vitro. In addition, suramin reduces the invasion phenotype in a zebrafish model. These results point suramin as a potential therapeutic agent in CRC.
To cite this abstract in AMA style:Zaragoza Huesca D, Ródenas M, Peñas-Martínez J, Pardo Sánchez I, Ortega Sabater C, Peña García J, Espín S, Ricote Sánchez G, Montenegro Luis S, Ayala de la peña F, Luengo Gil G, Nieto Olivares A, García Molina F, Vicente V, Bernardi F, Mulero V, Pérez-Sánchez H, Carmona Bayonas A, Martínez Martínez I. Suramin is a Hepsin inhibitor which reduces its protumor and prothrombotic effects in colorectal cancer cells [abstract]. https://abstracts.isth.org/abstract/suramin-is-a-hepsin-inhibitor-which-reduces-its-protumor-and-prothrombotic-effects-in-colorectal-cancer-cells/. Accessed September 26, 2022.
« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/suramin-is-a-hepsin-inhibitor-which-reduces-its-protumor-and-prothrombotic-effects-in-colorectal-cancer-cells/